eXoZymes Inc. (NASDAQ: EXOZ) has reported a tenfold improvement in manufacturing productivity for N-trans-caffeoyltyramine (NCT), a natural product molecule targeting nutraceutical and pharmaceutical applications.
The Los Angeles-based biotech firm optimized its enzyme-based NCT production process, achieving a 67% increase in yield per liter compared with a prior 100-liter pilot run. Reaction time was reduced by more than 80%, while internal cost assessments indicate the manufacturing cost equivalent has declined by over 100-fold from the initial process version.
The company’s 100-liter NCT pilot and validation work was conducted in collaboration with Cayman Chemical. eXoZymes has since focused on refining the process to enhance productivity, speed, simplicity, and commercial readiness, according to Paul Opgenorth, Vice President of Development and co-founder.
Damien Perriman, Chief Commercial Officer, stated that the progress has moved NCT from concept to a viable biosolution within less than two years, surpassing original commercial launch targets for performance and cost efficiency. The company is now advancing technology transfer to commercial manufacturing partners, pursuing commercialization through partnerships, licensing, and joint ventures.
Founded in 2019, eXoZymes develops enzyme-based technologies for producing natural product molecules, including NCT, cannabinoid analogs, and other compounds for nutraceutical and pharmaceutical markets.
